Evidence map›Paper›PMID 27274356›Full record

ArticleBiotechnology for biofuels2016

A xylose-stimulated xylanase-xylose binding protein chimera created by random nonhomologous recombination.

Lucas Ferreira Ribeiro, Jennifer Tullman, Nathan Nicholes, Sérgio Ruschi Bergamachi Silva, Davi Serradella Vieira, Marc Ostermeier, Richard John Ward

Open access · goldAbstract read
In one paragraph

Article in Biotechnology for biofuels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. ProspectingJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Engineering Allostery into Proteins.Advances in experimental medicine and biology · 2019
    Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lucas Ferreira RibeiroJohns Hopkins University, Baltimore, MD USA ; Departamento de Bioquímica e Imunologia, FMRP-Universidade de São Paulo-USP, Ribeirão Preto, SP Brazil.
Jennifer TullmanJohns Hopkins University, Baltimore, MD USA ; Institute for Bioscience and Biotechnology Research, Rockville, MD USA.
Nathan NicholesJohns Hopkins University, Baltimore, MD USA.
Sérgio Ruschi Bergamachi SilvaUniversidade Federal do Rio Grande do Norte, Natal, Brazil.
Davi Serradella VieiraUniversidade Federal do Rio Grande do Norte, Natal, Brazil.
Marc OstermeierJohns Hopkins University, Baltimore, MD USA.
Richard John WardLaboratório Nacional de Ciência e Tecnologia do Bioetanol-CTBE, Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), Campinas, SP Brazil ; Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, SP 14040-901 Brazil.
Johns Hopkins University · USUniversidade Federal do Rio Grande do Norte · BRLaboratório Nacional de Ciência e Tecnologia do Bioetanol · BR

Funding

The Combinatorial Design of Protein Molecular SwitchesR01GM066972 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI OSTERMEIER, MARC A · 2003 to 2016
$4.0M
NIGMS NIH HHS R01 GM066972
6 · The paper itself

Abstract

backgroundSaccharification of lignocellulosic material by xylanases and other glycoside hydrolases is generally conducted at high concentrations of the final reaction products, which frequently inhibit the enzymes used in the saccharification process. Using a random nonhomologous recombination strategy, we have fused the GH11 xylanase from Bacillus subtilis (XynA) with the xylose binding protein from Escherichia coli (XBP) to produce an enzyme that is allosterically stimulated by xylose.

resultsThe pT7T3GFP_XBP plasmid containing the XBP coding sequence was randomly linearized with DNase I, and ligated with the XynA coding sequence to create a random XynA-XBP insertion library, which was used to transform E. coli strain JW3538-1 lacking the XBP gene. Screening for active XBP was based on the expression of GFP from the pT7T3GFP_XBP plasmid under the control of a xylose inducible promoter. In the presence of xylose, cells harboring a functional XBP domain in the fusion protein (XBP+) showed increased GFP fluorescence and were selected using FACS. The XBP+ cells were further screened for xylanase activity by halo formation around xylanase producing colonies (XynA+) on LB-agar-xylan media after staining with Congo red. The xylanase activity ratio with xylose/without xylose in supernatants from the XBP+/XynA+ clones was measured against remazol brilliant blue xylan. A clone showing an activity ratio higher than 1.3 was selected where the XynA was inserted after the asparagine 271 in the XBP, and this chimera was denominated as XynA-XBP271. The XynA-XBP271 was more stable than XynA at 55 °C, and in the presence of xylose the catalytic efficiency was ~3-fold greater than the parental xylanase. Molecular dynamics simulations predicted the formation of an extended protein-protein interface with coupled movements between the XynA and XBP domains. In the XynA-XBP271 with xylose bound to the XBP domain, the mobility of a β-loop in the XynA domain results in an increased access to the active site, and may explain the observed allosteric activation.

conclusionsThe approach presented here provides an important advance for the engineering enzymes that are stimulated by the final product.

Indexed as

Allosteric regulationDirected evolutionEnzyme engineeringMolecular dynamics simulationNonhomologous recombinationXylanase

Identifiers

PMID27274356
PMCPMC4896006
OpenAlexW2416997112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.